Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentaethylene Glycol SCHEMBL1627452 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Triethylene Glycol SCHEMBL1573538 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Triethylene Glycol SCHEMBL816783 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Tetraethylene Glycol SCHEMBL236335 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Hexaethylene Glycol SCHEMBL875412 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Triethylene Glycol SCHEMBL874011 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Triethylene Glycol SCHEMBL854457 | 1.00 | MEN1 (0.69) | MEN1KMT2ATSHRMAPK1THRB | |
| Di(Hydroxyethyl)Ether SCHEMBL125344 | 0.97 | TSHR (0.67) | MEN1KMT2ATSHRMAPK1THRB | |
| Di(Hydroxyethyl)Ether SCHEMBL28090651 | 0.97 | TSHR (0.67) | MEN1KMT2ATSHRMAPK1THRB | |
| Di(Hydroxyethyl)Ether SCHEMBL8621256 | 0.97 | TSHR (0.67) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150004097-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | IKARIA THERAPEUTICS LLC | 2015-01-01 | — | — | US | disclosed |
| US-8871189-B2 | MMP-targeted therapeutic and/or diagnostic nanocarriers | MALLINCKRODT LLC (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2785635-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | Mallinckrodt LLC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20130183236-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | MALLINCKRODT INC. (US) | 2013-07-18 | — | — | US | disclosed |
| WO-2013082389-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | MALLINCKRODT INC. (US) | 2013-06-06 | — | — | WO | disclosed |
| US-20120082616-A1 | Aptamer Conjugates for Targeting of Therapeutic and/or Diagnostic Nanocarriers | MALLINCKRODT LLC (US) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130183236-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | MMP3, MMP9, MMP17 | MEN1 2905/4885KMT2A 2837/4885TSHR 3349/4885 |
| US-20150004097-A1 | MMP-TARGETED THERAPEUTIC AND/OR DIAGNOSTIC NANOCARRIERS | MMP3, MMP9, MMP17 | MEN1 2905/4885KMT2A 2837/4885TSHR 3349/4885 |
| US-20120082616-A1 | Aptamer Conjugates for Targeting of Therapeutic and/or Diagnostic Nanocarriers | EPHA2, ANXA6, SLC10A1 | MEN1 2323/4885KMT2A 1255/4885TSHR 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.